Fosun Kite Bags First China CAR-T Green Light
Commerical Battle Kicks Off
Executive Summary
Confounding earlier speculation, the first CAR-T cell therapy to gain approval in China is from the Fosun-Kite joint venture rather than Juno-WuXi AppTec. But pricing and market competition challenges are just beginning.
You may also be interested in...
Pandemic Drives China Surge In Asia 100 Sales
Notable new entrants moved into the Asia 100 this year, with growth catalyzed by COVID-19 vaccines.
Finance Watch: VC Mega-Rounds Surge Again, Led By Acelyrin’s $300m Series C
Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals.
Oncology, Cell Therapy Developers Bag $175m In China
Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.